Study of New Molecular Probes 18FAV45A and 18FAV1451Tau PETCT Scans to Diagnose Early Alzheimers Disease Changes

What this Trial Is About

Researchers are investigating the early brain regions involved in Alzheimers disease and its precursors using novel molecular probes 18FAV45 Ab2 and 18FAV1451 Tau with PETCT imaging. This study aims to understand the distribution of positive brain lesions affecting mental state tests like the simple mental state examination and the Montreal Cognitive Assessment Scale in Alzheimers patients. The goal is to provide molecular imaging information that may help study Alzheimers disease mechanisms and establish objective diagnostic criteria for early detection. The study uses new imaging agents Ab2 and Tau PETCT, which can detect pathological changes at the molecular level before symptoms appear. These molecular probes offer earlier and more visual detection of Alzheimers disease-related changes, helping to define positive diagnostic criteria for early Alzheimers disease. Participants include groups with mild cognitive impairment, Alzheimers disease, and healthy volunteers. Participants will be assessed through PETCT imaging using these molecular probes to observe brain pathology. Researchers will evaluate the diagnostic criteria for Ab2 and Tau imaging within two months. The study includes cognitive tests and clinical dementia rating scales. This observational study involves healthy volunteers and patients with mild cognitive impairment or Alzheimers disease, aiming to improve early diagnosis through imaging techniques.

[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease